{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 56,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/12",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.43,
        "y": 0.42
      },
      "kind": "chart",
      "text": "IFNy (pg/mL) activation",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbced5e0-d0aa-4d79-9e41-7eea52e916d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.15,
        "x": 0.11,
        "y": 0.42
      },
      "kind": "chart",
      "text": "BCMA Expression (MFI) in AL patients",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d672d6a2-d7dc-406d-95fa-79eb90c0e2e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.68,
        "y": 0.42
      },
      "kind": "chart",
      "text": "Flow cytometry showing plasma cell elimination",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cf821af-a090-4e9d-9c81-6a7c4edf632d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "a) Uneven BCMA expression and b) frail patient condition has historically prevented conventional, approved CAR-T use in AL Amyloidosis. NXC-201 was designed and tested for human AL Amyloidosis treatment, with preclinical testing revealing that:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47709ac5-14e0-4971-a3c6-1b0b295d8041",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "NXC-201's uniquely favorable tolerability profile (no neurotoxicity + \"Single-day CRS\") combined with proven preclinical and clinical efficacy make NXC-201 uniquely suited to treat AL Amyloidosis.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "513b4502-322f-4865-9b98-f2f38797b532",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: NXC-201 (formerly NBI0101). Infy TNFa for two patients, AL1, AL2. Far right top right quartile selected diseased AL Amyloidosis plasma cell elimination. Far right graph after 33 days co-incubated with NXC-201. Source: Kfir-Erenfeld S, et al. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022; Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb15f4c8-17e5-4336-b09c-0c873baa01dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "title",
      "text": "ALL BCMA CAR-TS ARE NOT CREATED EQUAL",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bf24d6d-d7f1-43fa-b052-128e01f72798",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 Designed for High Activity Against Disease-causing AL Amyloidosis Plasma Cells",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e4178f4-cce9-4603-bd29-af1dca841533",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
      "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
      "position": 0,
      "objective": "What are the consequences of not adopting NXC-201?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}